Posted by & filed under Company Analysis, Growth & Valuation, Industry Analysis, Management Issues, Personal Finance.

Description: A member of the Sackler family that owns OxyContin’s maker directed the company to put a premium on selling high dosages of its potentially addicting painkillers, according to new disclosures in a lawsuit.

Source: NYTimes.com

Date: Jan 31, 2019

Link: https://www.nytimes.com/2019/01/31/health/opioids-purdue-pharma-sackler.html

Questions for discussion:

  • What does the article say to investors about risk?
  • Is there any way to deal with this sort of risk?

Leave a Reply

Your email address will not be published.